A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Brief description of study

This is a randomized, double-blind, multicenter Phase 3 clinical study. This study plans to enroll about 470 patients, all of whom have advanced non-squamous NSCLC who have progressed on or following EGFR TKI treatment. This study will evaluate the efficacy and safety of AK112 combined with pemetrexed and carboplatin versus placebo combined with pemetrexed and carboplatin in patients with advanced non-squamous NSCLC who progressed on or following EGFR TKI therapy.


Clinical Study Identifier: s23-00889
ClinicalTrials.gov Identifier: NCT05184712


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.